{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:34:13Z","timestamp":1788449653631,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Gilead Sciences, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40262-024-01453-5","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T20:51:55Z","timestamp":1732049515000},"page":"67-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Pharmacokinetics and Safety of Remdesivir in Phase I Participants with Varying Degrees of Renal Impairment"],"prefix":"10.1007","volume":"64","author":[{"given":"Haeyoung","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Humeniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiannis","family":"Koullias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8071-367X","authenticated-orcid":false,"given":"Aryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"issue":"2","key":"1453_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/ndt\/gfab303","volume":"37","author":"MK Sullivan","year":"2022","unstructured":"Sullivan MK, Lees JS, Drake TM, Docherty AB, Oates G, Hardwick HE, et al. Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK study: a prospective, multicentre cohort study. Nephrol Dial Transplant. 2022;37(2):271\u201384. https:\/\/doi.org\/10.1093\/ndt\/gfab303.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1453_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12882-022-02681-2","volume":"23","author":"EC Bjornstad","year":"2022","unstructured":"Bjornstad EC, Cutter G, Guru P, Menon S, Aldana I, House S, et al. SARS-CoV-2 infection increases risk of acute kidney injury in a bimodal age distribution. BMC Nephrol. 2022;23(1):63. https:\/\/doi.org\/10.1186\/s12882-022-02681-2.","journal-title":"BMC Nephrol"},{"issue":"1","key":"1453_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.xkme.2020.11.008","volume":"3","author":"SA Silver","year":"2021","unstructured":"Silver SA, Beaubien-Souligny W, Shah PS, Harel S, Blum D, Kishibe T, et al. The prevalence of acute kidney injury in patients hospitalized with COVID-19 infection: a systematic review and meta-analysis. Kidney Med. 2021;3(1):83\u201398. https:\/\/doi.org\/10.1016\/j.xkme.2020.11.008.","journal-title":"Kidney Med."},{"issue":"12","key":"1453_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41581-020-00356-5","volume":"16","author":"MK Nadim","year":"2020","unstructured":"Nadim MK, Forni LG, Mehta RL, Connor MJ Jr, Liu KD, Ostermann M, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16(12):747\u201364. https:\/\/doi.org\/10.1038\/s41581-020-00356-5.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"1453_CR5","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s11255-020-02451-9","volume":"52","author":"BM Henry","year":"2020","unstructured":"Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol. 2020;52(6):1193\u20134. https:\/\/doi.org\/10.1007\/s11255-020-02451-9.","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"1453_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268688","volume":"17","author":"A Sato","year":"2022","unstructured":"Sato A, Ludwig J, Howell T. A retrospective cohort study on COVID-19 at 2 Los Angeles hospitals: older age, low triage oxygenation, and chronic kidney disease among the top risk factors associated with in-hospital mortality. PLoS ONE. 2022;17(6): e0268688. https:\/\/doi.org\/10.1371\/journal.pone.0268688.","journal-title":"PLoS ONE"},{"issue":"24","key":"1453_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029362","volume":"101","author":"W Huang","year":"2022","unstructured":"Huang W, Li B, Jiang N, Zhang F, Shi W, Zuo L, et al. Impact of the COVID-19 pandemic on patients with chronic kidney disease: a narrative review. Medicine (Baltimore). 2022;101(24): e29362. https:\/\/doi.org\/10.1097\/MD.0000000000029362.","journal-title":"Medicine (Baltimore)"},{"key":"1453_CR8","doi-asserted-by":"publisher","first-page":"1250631","DOI":"10.3389\/fmed.2023.1250631","volume":"10","author":"M He","year":"2023","unstructured":"He M, Wang Y, Li S, Gillespie A. Nationwide in-hospital mortality and morbidity analysis of COVID-19 in advanced chronic kidney disease, dialysis and kidney transplant recipients. Front Med (Lausanne). 2023;10:1250631. https:\/\/doi.org\/10.3389\/fmed.2023.1250631.","journal-title":"Front Med (Lausanne)."},{"issue":"20","key":"1453_CR9","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","volume":"295","author":"CJ Gordon","year":"2020","unstructured":"Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785\u201397. https:\/\/doi.org\/10.1074\/jbc.RA120.013679.","journal-title":"J Biol Chem"},{"key":"1453_CR10","unstructured":"Gilead Sciences. Veklury\u00ae (remdesivir) [prescribing information]. Gilead Sciences, Inc.; July 2023."},{"key":"1453_CR11","unstructured":"Gilead Sciences. Veklury summary of product characteristics.Gilead Sciences Ireland UC; May 2023."},{"key":"1453_CR12","unstructured":"Gilead Sciences. FDA approves Veklury\u00ae (remdesivir) to treat COVID-19 in people with mild to severe hepatic impairment with no dose adjustment. Available from: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2023\/8\/fda-approves-veklury-remdesivir-to-treat-covid19-in-people-with-mild-to-severe-hepatic-impairment-with-no-dose-adjustment. Accessed 11 Jan 2024."},{"issue":"5","key":"1453_CR13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/cts.12840","volume":"13","author":"R Humeniuk","year":"2020","unstructured":"Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G, Chng E, et al. Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects. Clin Transl Sci. 2020;13(5):896\u2013906. https:\/\/doi.org\/10.1111\/cts.12840.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"1453_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40262-021-00984-5","volume":"60","author":"R Humeniuk","year":"2021","unstructured":"Humeniuk R, Mathias A, Kirby BJ, Lutz JD, Cao H, Osinusi A, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor. Clin Pharmacokinet. 2021;60(5):569\u201383. https:\/\/doi.org\/10.1007\/s40262-021-00984-5.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1453_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3390\/ph14070655","volume":"14","author":"S Deb","year":"2021","unstructured":"Deb S, Reeves AA, Hopefl R, Bejusca R. ADME and pharmacokinetic properties of remdesivir: its drug interaction potential. Pharmaceuticals (Basel). 2021;14(7):655. https:\/\/doi.org\/10.3390\/ph14070655.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1453_CR16","unstructured":"Gilead Sciences. CHMP adopts positive opinion to extend the use of Veklury\u00ae (remdesivir) to treat COVID-19 in people with severe renal impairment, including those on dialysis. Available from: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2023\/5\/chmp-adopts-positive-opinion-to-extend-the-use-of-veklury-remdesivir-to-treat-covid19-in-people-with-severe-renal-impairment-including-those-on-d. Accessed 11 Jan 2024."},{"key":"1453_CR17","unstructured":"Gilead Sciences. FDA approves Veklury\u00ae (remdesivir) for COVID-19 treatment in patients with severe renal impairment, including those on dialysis. Available from: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2023\/7\/fda-approves-veklury-remdesivir-for-covid19-treatment-in-patients-with-severe-renal-impairment-including-those-on-dialysis. Accessed 11 Jan 2024."},{"key":"1453_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/cid\/ciae333","volume":"2","author":"ME Sise","year":"2024","unstructured":"Sise ME, Santos JR, Goldman JD, Tuttle KR, Teixeira JP, Seibert AF, et al. The REDPINE study: efficacy and safety of remdesivir in people with impaired kidney function hospitalized for COVID-19 pneumonia: a randomized clinical trial. Clin Infect Dis. 2024;2:333. https:\/\/doi.org\/10.1093\/cid\/ciae333.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1453_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354. https:\/\/doi.org\/10.7326\/0003-4819-145-4-200608150-00004.","journal-title":"Ann Intern Med"},{"key":"1453_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2021.114118","volume":"617","author":"D Xiao","year":"2021","unstructured":"Xiao D, John Ling KH, Tarnowski T, Humeniuk R, German P, Mathias A, et al. Validation of LC-MS\/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies. Anal Biochem. 2021;617: 114118. https:\/\/doi.org\/10.1016\/j.ab.2021.114118.","journal-title":"Anal Biochem"},{"issue":"12","key":"1453_CR21","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1016\/j.xphs.2023.09.009","volume":"112","author":"A Wen","year":"2023","unstructured":"Wen A, Qin AR, Tarnowski T, Ling KHJ, Zhang H, Humeniuk R, et al. Plasma protein binding determination for unstable ester prodrugs: remdesivir and tenofovir alafenamide. J Pharm Sci. 2023;112(12):3224\u201332. https:\/\/doi.org\/10.1016\/j.xphs.2023.09.009.","journal-title":"J Pharm Sci"},{"issue":"8","key":"1453_CR22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","volume":"65","author":"RK Verbeeck","year":"2009","unstructured":"Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757\u201373. https:\/\/doi.org\/10.1007\/s00228-009-0678-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1453_CR23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/ki.2013.399","volume":"85","author":"CK Yeung","year":"2014","unstructured":"Yeung CK, Shen DD, Thummel KE, Himmelfarb J. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int. 2014;85(3):522\u20138. https:\/\/doi.org\/10.1038\/ki.2013.399.","journal-title":"Kidney Int"},{"issue":"3","key":"1453_CR24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/cpt.757","volume":"102","author":"JO Miners","year":"2017","unstructured":"Miners JO, Yang X, Knights KM, Zhang L. The role of the kidney in drug elimination: transport, metabolism, and the impact of kidney disease on drug clearance. Clin Pharmacol Ther. 2017;102(3):436\u201349. https:\/\/doi.org\/10.1002\/cpt.757.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1453_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","volume":"49","author":"MJ Hanley","year":"2010","unstructured":"Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71\u201387. https:\/\/doi.org\/10.2165\/11318100-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1453_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115281","volume":"166","author":"J Gouju","year":"2023","unstructured":"Gouju J, Legeay S. Pharmacokinetics of obese adults: not only an increase in weight. Biomed Pharmacother. 2023;166: 115281. https:\/\/doi.org\/10.1016\/j.biopha.2023.115281.","journal-title":"Biomed Pharmacother"},{"issue":"19","key":"1453_CR27","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19\u2014final report. N Engl J Med. 2020;383(19):1813\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2007764.","journal-title":"N Engl J Med"},{"issue":"4","key":"1453_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"RL Gottlieb","year":"2022","unstructured":"Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med. 2022;386(4):305\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2116846.","journal-title":"N Engl J Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01453-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01453-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01453-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T09:51:33Z","timestamp":1737798693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01453-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01453-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"31 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Gilead Sciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are stockholders and either current or past employees of Gilead Sciences, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The dataset supporting the results of this study is available upon reasonable request. Inquiries can be directed to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The trial was conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation good clinical practice guidelines, consistent with the requirements of the US Code of Federal Regulations Title 21, Part 312, the European Community Directive 2001\/20\/EC, and other local legislation. This study was approved by a duly constituted independent ethics committee or institutional review board at each study site (approval number, date: Pro00046464, 15 Sep 2014; SSU00132267, 28 Sep 2020; SSU00132670, 30 Oct 2020; SSU00134955, 2 Nov 2020; SSU00135391, 17 Nov 2020; SSU00135407, 17 Nov 2020; SSU00135579, 18 Nov 2020; SSU00136760, 23 Nov 2020; SSU00132957, 4 Mar 2021; SSU00133322, 9 Mar 2021; SSU00144548, 10 Mar 2021; 705\/20 Af-KK, 9 Feb 2021; 20\/CEN\/248, 10 December 2020).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed written consent was obtained from all participants before study participation.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All study participants provided consent for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Haeyoung Zhang, Rita Humeniuk, Yiannis Koullias, and Robert H. Hyland contributed to the design of the study. Haeyoung Zhang, Sean Regan, Amy John, and Deqing Xiao contributed to the acquisition of data. Haeyoung Zhang, Sean Regan, Yiannis Koullias, Santosh Davies, and Gong Shen analyzed the data. Haeyoung Zhang, Rita Humeniuk, Yiannis Koullias, Santosh Davies, Robert H. Hyland, Helen Winter, and Aryun Kim contributed to the interpretation of the data. All authors critically reviewed the manuscript and approved the final manuscript for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}